224 related articles for article (PubMed ID: 29052538)
1. Antimicrobial Resistance in
Giguère S; Berghaus LJ; Willingham-Lane JM
Microbiol Spectr; 2017 Oct; 5(5):. PubMed ID: 29052538
[TBL] [Abstract][Full Text] [Related]
2. Determination of the prevalence of antimicrobial resistance to macrolide antimicrobials or rifampin in Rhodococcus equi isolates and treatment outcome in foals infected with antimicrobial-resistant isolates of R equi.
Giguère S; Lee E; Williams E; Cohen ND; Chaffin MK; Halbert N; Martens RJ; Franklin RP; Clark CC; Slovis NM
J Am Vet Med Assoc; 2010 Jul; 237(1):74-81. PubMed ID: 20590498
[TBL] [Abstract][Full Text] [Related]
3. Emergence of Resistance to Macrolides and Rifampin in Clinical Isolates of Rhodococcus equi from Foals in Central Kentucky, 1995 to 2017.
Huber L; Giguère S; Slovis NM; Carter CN; Barr BS; Cohen ND; Elam J; Erol E; Locke SJ; Phillips ED; Smith JL
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373803
[TBL] [Abstract][Full Text] [Related]
4. Mutant prevention concentration and mutant selection window for 10 antimicrobial agents against Rhodococcus equi.
Berghaus LJ; Giguère S; Guldbech K
Vet Microbiol; 2013 Oct; 166(3-4):670-5. PubMed ID: 23915992
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Infections Caused by Rhodococcus equi.
Giguère S
Vet Clin North Am Equine Pract; 2017 Apr; 33(1):67-85. PubMed ID: 28161038
[TBL] [Abstract][Full Text] [Related]
6. Effect of Macrolide and Rifampin Resistance on the Fitness of Rhodococcus equi.
Willingham-Lane JM; Berghaus LJ; Berghaus RD; Hart KA; Giguère S
Appl Environ Microbiol; 2019 Apr; 85(7):. PubMed ID: 30683740
[No Abstract] [Full Text] [Related]
7. Novel transferable erm(46) determinant responsible for emerging macrolide resistance in Rhodococcus equi.
Anastasi E; Giguère S; Berghaus LJ; Hondalus MK; Willingham-Lane JM; MacArthur I; Cohen ND; Roberts MC; Vazquez-Boland JA
J Antimicrob Chemother; 2015 Dec; 70(12):3184-90. PubMed ID: 26377866
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and risk factors associated with emergence of Rhodococcus equi resistance to macrolides and rifampicin in horse-breeding farms in Kentucky, USA.
Huber L; Giguère S; Cohen ND; Slovis NM; Hanafi A; Schuckert A; Berghaus L; Greiter M; Hart KA
Vet Microbiol; 2019 Aug; 235():243-247. PubMed ID: 31383308
[TBL] [Abstract][Full Text] [Related]
9. Effect of Macrolide and Rifampin Resistance on Fitness of
Willingham-Lane JM; Berghaus LJ; Berghaus RD; Hart KA; Giguère S
Infect Immun; 2019 Oct; 87(10):. PubMed ID: 31331959
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial susceptibility patterns of Rhodococcus equi from necropsied foals with rhodococcosis.
Erol E; Locke S; Saied A; Cruz Penn MJ; Smith J; Fortner J; Carter C
Vet Microbiol; 2020 Mar; 242():108568. PubMed ID: 32122582
[TBL] [Abstract][Full Text] [Related]
11. In vitro synergy, pharmacodynamics, and postantibiotic effect of 11 antimicrobial agents against Rhodococcus equi.
Giguère S; Lee EA; Guldbech KM; Berghaus LJ
Vet Microbiol; 2012 Nov; 160(1-2):207-13. PubMed ID: 22704561
[TBL] [Abstract][Full Text] [Related]
12. Clonal Confinement of a Highly Mobile Resistance Element Driven by Combination Therapy in Rhodococcus equi.
Álvarez-Narváez S; Giguère S; Anastasi E; Hearn J; Scortti M; Vázquez-Boland JA
mBio; 2019 Oct; 10(5):. PubMed ID: 31615959
[TBL] [Abstract][Full Text] [Related]
13. Identification of macrolide- and rifampicin-resistant Rhodococcus equi in environmental samples from equine breeding farms in central Kentucky during 2018.
Huber L; Giguère S; Cohen ND; Slovis NM; Berghaus L; Greiter M; Hart KA
Vet Microbiol; 2019 May; 232():74-78. PubMed ID: 31030848
[TBL] [Abstract][Full Text] [Related]
14. Disposition of oral telithromycin in foals and in vitro activity of the drug against macrolide-susceptible and macrolide-resistant Rhodococcus equi isolates.
Javsicas LH; Giguère S; Womble AY
J Vet Pharmacol Ther; 2010 Aug; 33(4):383-8. PubMed ID: 20646201
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin, and 20 other antimicrobials.
Jacks SS; Giguère S; Nguyen A
Antimicrob Agents Chemother; 2003 May; 47(5):1742-5. PubMed ID: 12709351
[TBL] [Abstract][Full Text] [Related]
16. The novel and transferable erm(51) gene confers macrolides, lincosamides and streptogramins B (MLS
Huber L; Giguère S; Slovis NM; Álvarez-Narváez S; Hart KA; Greiter M; Morris ERA; Cohen ND
Environ Microbiol; 2020 Jul; 22(7):2858-2869. PubMed ID: 32291839
[TBL] [Abstract][Full Text] [Related]
17. Chemoprophylactic effects of azithromycin against Rhodococcus equi-induced pneumonia among foals at equine breeding farms with endemic infections.
Chaffin MK; Cohen ND; Martens RJ
J Am Vet Med Assoc; 2008 Apr; 232(7):1035-47. PubMed ID: 18380623
[TBL] [Abstract][Full Text] [Related]
18. Acquired antimicrobial resistance in equine Rhodococcus equi isolates.
Boyen F; Pasmans F; Haesebrouck F
Vet Rec; 2011 Jan; 168(4):101a. PubMed ID: 21257598
[No Abstract] [Full Text] [Related]
19. Retrospective comparison of azithromycin, clarithromycin, and erythromycin for the treatment of foals with Rhodococcus equi pneumonia.
Giguère S; Jacks S; Roberts GD; Hernandez J; Long MT; Ellis C
J Vet Intern Med; 2004; 18(4):568-73. PubMed ID: 15320600
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial resistance among
Lord J; Carter C; Smith J; Locke S; Phillips E; Odoi A
PeerJ; 2022; 10():e13682. PubMed ID: 36164606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
